Shujun Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shujun Luo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Weisz
Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi, Italy
1 shared publication - Gary P. Schroth
Illumina, Inc
1 shared publication - Giorgio Giurato
Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi, Italy
1 shared publication - Giovanni Nassa
Department of General Pathology, Second University of Naples, vico L. De Crecchio 7, 80138 Napoli, Italy
1 shared publication - Lorenzo Ferraro
Department of General Pathology, Second University of Naples, vico L. De Crecchio 7, 80138 Napoli, Italy
1 shared publication - Luigi Cicatiello
Department of General Pathology, Second University of Naples, vico L. De Crecchio 7, 80138 Napoli, Italy
1 shared publication
Latest Publications
- 1 December 2011
- Published by Springer Nature
- Vol. 822, 183-188
MicroRNA Expression Analysis Using the Illumina MicroRNA-Seq Platform
Direct sequencing of RNA molecules using next-generation sequencing (NGS) technology has revolutionized the analysis of transcriptome with its massively parallel throughput and low cost. Here, we describe Illumina’s microRNA-Seq, a method for sequencing microRNA using the Illumina Genome Analyzer system. The sequence data generated from this method enables direct identifying and profiling of microRNAs in any given organism. It also sheds light in understanding the biogenesis and modification of microRNA.
- 1 December 2011
- Published by Springer Nature
- Vol. 822, 183-188
MicroRNA Expression Analysis Using the Illumina MicroRNA-Seq Platform
Direct sequencing of RNA molecules using next-generation sequencing (NGS) technology has revolutionized the analysis of transcriptome with its massively parallel throughput and low cost. Here, we describe Illumina’s microRNA-Seq, a method for sequencing microRNA using the Illumina Genome Analyzer system. The sequence data generated from this method enables direct identifying and profiling of microRNAs in any given organism. It also sheds light in understanding the biogenesis and modification of microRNA.
- Open Access
- 14 January 2011
- Published by Springer Nature in BMC Genomics
- Vol. 12 (1) , 36
Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation
Background: Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors (TFs) that mediate estrogen signaling and define the hormone-responsive phenotype of breast cancer (BC). The two receptors can be found co-expressed and play specific, often opposite, roles, with ERβ being able to modulate the effects of ERα on gene transcription and cell proliferation. ERβ is frequently lost in BC, where its presence generally correlates with a better prognosis of the disease. The identification of the genomic targets of ERβ in hormone-responsive BC cells is thus a critical step to elucidate the roles of this receptor in estrogen signaling and tumor cell biology. Results: Expression of full-length ERβ in hormone-responsive, ERα-positive MCF-7 cells resulted in a marked reduction in cell proliferation in response to estrogen and marked effects on the cell transcriptome. By ChIP-Seq we identified 9702 ERβ and 6024 ERα binding sites in estrogen-stimulated cells, comprising sites occupied by either ERβ, ERα or both ER subtypes. A search for TF binding matrices revealed that the majority of the binding sites identified comprise one or more Estrogen Response Element and the remaining show binding matrixes for other TFs known to mediate ER interaction with chromatin by tethering, including AP2, E2F and SP1. Of 921 genes differentially regulated by estrogen in ERβ+ vs ERβ- cells, 424 showed one or more ERβ site within 10 kb. These putative primary ERβ target genes control cell proliferation, death, differentiation, motility and adhesion, signal transduction and transcription, key cellular processes that might explain the biological and clinical phenotype of tumors expressing this ER subtype. ERβ binding in close proximity of several miRNA genes and in the mitochondrial genome, suggests the possible involvement of this receptor in small non-coding RNA biogenesis and mitochondrial genome functions. Conclusions: Results indicate that the vast majority of the genomic targets of ERβ can bind also ERα, suggesting that the overall action of ERβ on the genome of hormone-responsive BC cells depends mainly on the relative concentration of both ERs in the cell.
- 14 January 2011
- Published by Springer Nature in BMC Genomics
- Vol. 12 (1) , 36
Open AccessGlobal analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation
Background: Estrogen receptors alpha (ERα) and beta (ERβ) are transcription factors (TFs) that mediate estrogen signaling and define the hormone-responsive phenotype of breast cancer (BC). The two receptors can be found co-expressed and play specific, often opposite, roles, with ERβ being able to modulate the effects of ERα on gene transcription and cell proliferation. ERβ is frequently lost in BC, where its presence generally correlates with a better prognosis of the disease. The identification of the genomic targets of ERβ in hormone-responsive BC cells is thus a critical step to elucidate the roles of this receptor in estrogen signaling and tumor cell biology. Results: Expression of full-length ERβ in hormone-responsive, ERα-positive MCF-7 cells resulted in a marked reduction in cell proliferation in response to estrogen and marked effects on the cell transcriptome. By ChIP-Seq we identified 9702 ERβ and 6024 ERα binding sites in estrogen-stimulated cells, comprising sites occupied by either ERβ, ERα or both ER subtypes. A search for TF binding matrices revealed that the majority of the binding sites identified comprise one or more Estrogen Response Element and the remaining show binding matrixes for other TFs known to mediate ER interaction with chromatin by tethering, including AP2, E2F and SP1. Of 921 genes differentially regulated by estrogen in ERβ+ vs ERβ- cells, 424 showed one or more ERβ site within 10 kb. These putative primary ERβ target genes control cell proliferation, death, differentiation, motility and adhesion, signal transduction and transcription, key cellular processes that might explain the biological and clinical phenotype of tumors expressing this ER subtype. ERβ binding in close proximity of several miRNA genes and in the mitochondrial genome, suggests the possible involvement of this receptor in small non-coding RNA biogenesis and mitochondrial genome functions. Conclusions: Results indicate that the vast majority of the genomic targets of ERβ can bind also ERα, suggesting that the overall action of ERβ on the genome of hormone-responsive BC cells depends mainly on the relative concentration of both ERs in the cell.